HomeOpen Access NewsPharmaceutical Industry

Pharmaceutical Industry

Why the pharmaceutical industry must go green

Health Care Without Harm aims to transform global healthcare to minimize its environmental impact and promote sustainability. Lorna Rothery spoke to the team about the effects of pharmaceutical pollution and the necessity for the industry to adopt greener practices.

Zebra Technologies: Dedicated to improving global health

We spoke with Tony Cecchin, Vice President and General Manager of Global Supplies at Zebra Technologies and President of Temptime Corporation, and Chris Caulfield, Vice President of Temptime Operations about their work supporting front-line workers and easing the shipment of medical products through the supply chain.

Benchmarking Regulatory systems governing veterinary medicines

Rick Clayton, Technical Director, AnimalhealthEurope, unpacks Benchmarking Regulatory systems governing veterinary medicines in this the first of a series of three articles.

Pharmaceuticals: Falsified medicines

Dr Ash Ramzan, Founder and Principal Consultant, Woodley BioReg Limited, turns the spotlight on falsified medicines in this pharmaceuticals focus.

Why are illegal pharma markets still prevalent today?

Professor Luis Diestre discusses the research and findings of his European Research Council funded Illegal Pharma Project, focussing on the ever popular market for counterfeit pharmaceuticals.

Cannabidiol, skin homeostasis and acne

Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains the potential of CBD and cannabinoids for skin care.

The UK’s legalisation of medicinal cannabis

David Hardstaff of BCL’s Cannabis Law & Regulatory team considers the success of the UK’s legalisation of medicinal cannabis products.

Targeted policy support for emerging biomedical innovations

Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.

COVID-19 update: Vaccinations & infection prevention and control (IPC)

Ruth Smith CEO of Active Care Group and its Christchurch Group division discusses the new highly virulent variant of COVID, vaccinations, and infection prevention and control (IPC).

EU allocates additional €500 million to COVAX facility

The European Union has allocated an additional €500 million to the COVAX facility, bringing its total contribution to €1 billion.

Heart failure drug may treat COVID-19 long-hauler symptom

Researchers have found that an existing heart failure drug can improve the symptoms associated with postural orthostatic tachycardia syndrome.

COVID-19 and drugs in the European neighbourhood partnership countries

The EU drugs agency explores the impact of COVID-19 on drug markets, use and services in the European neighbourhood partnership countries.

Medical cannabis in the UK and the industry’s future

Rick Brar, CEO & Chairman of Brains Bioceutical Corp. explores the landscape of medical cannabis in the UK and the future direction of the industry.

UK Government and CureVac partnership to tackle COVID-19 virus variants

The UK Government and vaccine manufacturer CureVac have partnered to rapidly develop new vaccines in response to new COVID-19 virus variants.

UK regulator assures safety of COVID-19 vaccines

Recent data published by the UK’s independent medicines regulator assures the Pfizer/BioNTech and the Oxford University/AstraZeneca vaccines meet strict regulatory standards for safety

Innovate UK invests £900k into cloud-based pharmacy dispensary software

Innovate UK has invested a further £900k of funding into Titan, a cloud-based medicine dispensary software for pharmacies.

Drug prices in the U.S. are 2.56 times higher

Prescription drug prices in the United States are 2.56 times higher than in other countries, according to a new RAND Corporation report.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders